NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its allogeneic mesenchymal precursor cell product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD).
The trial results will be delivered in a late-breaking clinical science session at the 2018 American Heart Association Scientific Sessions in Chicago this Sunday by independent investigators from the United States National Institutes of Health (NIH) Cardiothoracic Surgical Trials Network. The trial is being funded and sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) of the NIH, and the Canadian Institutes for Health Research.
The webcast will begin at 8.00am EST; 1.00pm BST Monday, November 12; and 12:00am AEDT Tuesday, November 13, 2018. To access the call only, dial 1 855 881 1339 (U.S.), 0800 051 8245 (toll free U.K.), 1 800 558 698 (toll free Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 867444.
The live webcast can be accessed via http://webcasting.boardroom.media/broadcast/5bdfe30db7b1cf2eab18cf12 and the archived webcast will be available on the Investor page of the Company’s website.
About Mesoblast
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com
| For further information, please contact: | |||
| Julie Meldrum | Schond Greenway | ||
| Corporate Communications | Investor Relations | ||
| T: +61 3 9639 6036 | T: +1 212 880 2060 | ||
| T: +61 3 9639 6036 | T: +1 212 880 2060 | ||
| E: julie.meldrum@mesoblast.com | E: schond.greenway@mesoblast.com | ||